JP2014530802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530802A5 JP2014530802A5 JP2014518853A JP2014518853A JP2014530802A5 JP 2014530802 A5 JP2014530802 A5 JP 2014530802A5 JP 2014518853 A JP2014518853 A JP 2014518853A JP 2014518853 A JP2014518853 A JP 2014518853A JP 2014530802 A5 JP2014530802 A5 JP 2014530802A5
- Authority
- JP
- Japan
- Prior art keywords
- sustained
- pioglitazone
- release preparation
- preparation according
- polyethylene oxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 76
- 239000003405 delayed action preparation Substances 0.000 claims description 52
- 229960005095 pioglitazone Drugs 0.000 claims description 38
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 26
- 230000015572 biosynthetic process Effects 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000000748 compression moulding Methods 0.000 claims description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 229950008138 carmellose Drugs 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 6
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 claims description 4
- 229960002827 pioglitazone hydrochloride Drugs 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229960000913 crospovidone Drugs 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 2
- 238000007922 dissolution test Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011232302 | 2011-10-21 | ||
| JP2011232302 | 2011-10-21 | ||
| PCT/JP2012/077662 WO2013058409A1 (en) | 2011-10-21 | 2012-10-19 | Sustained-release preparation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530802A JP2014530802A (ja) | 2014-11-20 |
| JP2014530802A5 true JP2014530802A5 (OSRAM) | 2015-11-26 |
| JP6093762B2 JP6093762B2 (ja) | 2017-03-08 |
Family
ID=47178262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014518853A Expired - Fee Related JP6093762B2 (ja) | 2011-10-21 | 2012-10-19 | 徐放性製剤 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9907789B2 (OSRAM) |
| EP (1) | EP2768487B1 (OSRAM) |
| JP (1) | JP6093762B2 (OSRAM) |
| KR (1) | KR20140081826A (OSRAM) |
| CN (1) | CN104039313A (OSRAM) |
| AP (1) | AP2014007645A0 (OSRAM) |
| AR (1) | AR088398A1 (OSRAM) |
| AU (1) | AU2012326976B2 (OSRAM) |
| BR (1) | BR112014008744A2 (OSRAM) |
| CA (1) | CA2852417A1 (OSRAM) |
| CL (1) | CL2014000992A1 (OSRAM) |
| CO (1) | CO6960544A2 (OSRAM) |
| CR (1) | CR20140213A (OSRAM) |
| DO (1) | DOP2014000077A (OSRAM) |
| EA (1) | EA201490840A1 (OSRAM) |
| EC (1) | ECSP14013328A (OSRAM) |
| IL (1) | IL232114A0 (OSRAM) |
| IN (1) | IN2014DN03169A (OSRAM) |
| MA (1) | MA35717B1 (OSRAM) |
| MX (1) | MX2014004679A (OSRAM) |
| NZ (1) | NZ624275A (OSRAM) |
| PE (1) | PE20141189A1 (OSRAM) |
| PH (1) | PH12014500856A1 (OSRAM) |
| SG (2) | SG10201700121YA (OSRAM) |
| TN (1) | TN2014000152A1 (OSRAM) |
| TW (1) | TW201323018A (OSRAM) |
| UA (1) | UA113858C2 (OSRAM) |
| UY (1) | UY34403A (OSRAM) |
| WO (1) | WO2013058409A1 (OSRAM) |
| ZA (1) | ZA201403103B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9907789B2 (en) | 2011-10-21 | 2018-03-06 | Takeda Pharmaceutical Company Limited | Sustained-release preparation |
| US8987250B2 (en) | 2012-04-20 | 2015-03-24 | Gilead Sciences, Inc. | Therapeutic compounds |
| US20150141517A1 (en) * | 2013-11-15 | 2015-05-21 | Shin-Etsu Chemical Co., Ltd. | Granulated composite, rapid release tablet and method for producing same |
| KR102485766B1 (ko) | 2019-12-11 | 2023-01-09 | 한국유나이티드제약 주식회사 | 생체이용률이 향상된 피오글리타존 함유 약학조성물 |
| UY39094A (es) * | 2020-02-27 | 2021-07-30 | Hk Inno N Corp | Composición farmacéutica que comprende compuesto derivado de bencimidazol |
| JP2023066053A (ja) * | 2021-10-28 | 2023-05-15 | 東和薬品株式会社 | 放出制御医薬組成物 |
| WO2025064867A1 (en) * | 2023-09-21 | 2025-03-27 | Yuva Biosciences, Inc. | Delivery system for mitochondrial health enhancers |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810502A (en) | 1987-02-27 | 1989-03-07 | Alza Corporation | Pseudoephedrine brompheniramine therapy |
| US4820522A (en) | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| JPH0624991A (ja) | 1991-06-20 | 1994-02-01 | Tokyo Tanabe Co Ltd | ウルソデスオキシコール酸持続性製剤 |
| JPH0624959A (ja) | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | 胃内浮遊型薬物徐放性固形製剤 |
| HU226456B1 (en) | 1992-09-18 | 2008-12-29 | Astellas Pharma Inc | Sustained-release hydrogel preparation |
| JPH06316517A (ja) | 1993-02-22 | 1994-11-15 | Grelan Pharmaceut Co Ltd | 放出制御製剤 |
| WO1998056359A2 (de) | 1997-06-13 | 1998-12-17 | Roland Bodmeier | Zusammensetzungen, die die wirkstofffreisetzung verzögern |
| US6191154B1 (en) | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| CA2456034A1 (en) | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
| US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| CN100544717C (zh) | 2002-09-20 | 2009-09-30 | 华生制药公司 | 含有双胍和噻唑烷二酮衍生物的药物剂型 |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| JP4493970B2 (ja) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
| IN192749B (OSRAM) | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
| US7442387B2 (en) | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
| JP4933033B2 (ja) | 2003-03-17 | 2012-05-16 | 武田薬品工業株式会社 | 放出制御組成物 |
| CA2519208A1 (en) | 2003-03-17 | 2004-09-30 | Takeda Pharmaceutical Company Limited | Controlled release composition |
| CN1802178A (zh) | 2003-06-06 | 2006-07-12 | 武田药品工业株式会社 | 固体制剂 |
| JP2005015477A (ja) | 2003-06-06 | 2005-01-20 | Takeda Chem Ind Ltd | 固形製剤 |
| US20060003002A1 (en) | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
| EP1738754B1 (en) | 2004-04-14 | 2015-07-15 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical preparation |
| CA2578474A1 (en) | 2004-08-31 | 2006-03-09 | Pfizer Products Inc. | Controlled release dosage forms combining immediate release and sustained release of low-solubility drug |
| EA200800879A1 (ru) | 2005-09-22 | 2008-10-30 | ЭсБи ФАРМКО ПУЭРТО РИКО ИНК. | Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов |
| WO2007054976A2 (en) | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd. | Lipid based controlled release pharmaceutical composition |
| JP5179363B2 (ja) | 2005-12-22 | 2013-04-10 | 武田薬品工業株式会社 | 固形製剤 |
| US8367107B2 (en) | 2006-03-30 | 2013-02-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Solid pharmaceutical preparation |
| CL2007001195A1 (es) | 2006-04-27 | 2008-01-04 | Takeda Pharmaceutical | Composicion farmaceutica solida que comprende un nucleo con un compuesto derivado de bencimidazol y una grasa o aceite, una primera capa que comprende un polimero de alto peso molecular que recubre el nucleo y una segunda capa que comprende pioglitazona, util para tratar enfermedades circulatorias. |
| CA2677623C (en) | 2007-02-09 | 2015-04-07 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
| TW200914006A (en) * | 2007-07-12 | 2009-04-01 | Takeda Pharmaceutical | Coated preparation |
| CN101269040A (zh) | 2008-05-16 | 2008-09-24 | 北京正大绿洲医药科技有限公司 | 盐酸吡格列酮缓释滴丸及其制备方法 |
| CA2738930C (en) | 2008-09-30 | 2021-08-17 | The Trustees Of The University Of Pennsylvania | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
| TWI478712B (zh) * | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| EP2486918A4 (en) | 2009-10-09 | 2014-02-26 | Yungjin Pharmaceutical Co Ltd | PHARMACEUTICAL COMPOSITION WITH BOTH IMMEDIATE AND DELAYED RELEASE |
| JP2011232302A (ja) | 2010-04-30 | 2011-11-17 | Ricoh Elemex Corp | 画像検査方法及び画像検査装置 |
| CN101884627B (zh) | 2010-07-07 | 2012-01-25 | 青岛黄海制药有限责任公司 | 盐酸吡格列酮胃内滞留缓释片及其制备方法 |
| MA34828B1 (fr) | 2011-01-10 | 2014-01-02 | Zinfandel Pharmaceuticals Inc | Procédés et produits médicamenteux destinés au traitement de la maladie d'alzheimer |
| US9907789B2 (en) | 2011-10-21 | 2018-03-06 | Takeda Pharmaceutical Company Limited | Sustained-release preparation |
| KR20160056691A (ko) | 2014-11-12 | 2016-05-20 | 삼성에스디아이 주식회사 | 이차전지 |
-
2012
- 2012-10-19 US US14/352,785 patent/US9907789B2/en active Active
- 2012-10-19 UA UAA201405332A patent/UA113858C2/uk unknown
- 2012-10-19 AR ARP120103908A patent/AR088398A1/es unknown
- 2012-10-19 NZ NZ624275A patent/NZ624275A/en not_active IP Right Cessation
- 2012-10-19 IN IN3169DEN2014 patent/IN2014DN03169A/en unknown
- 2012-10-19 CN CN201280062591.4A patent/CN104039313A/zh active Pending
- 2012-10-19 EA EA201490840A patent/EA201490840A1/ru unknown
- 2012-10-19 BR BR112014008744A patent/BR112014008744A2/pt not_active IP Right Cessation
- 2012-10-19 AP AP2014007645A patent/AP2014007645A0/xx unknown
- 2012-10-19 TW TW101138592A patent/TW201323018A/zh unknown
- 2012-10-19 PE PE2014000558A patent/PE20141189A1/es not_active Application Discontinuation
- 2012-10-19 AU AU2012326976A patent/AU2012326976B2/en not_active Ceased
- 2012-10-19 SG SG10201700121YA patent/SG10201700121YA/en unknown
- 2012-10-19 MX MX2014004679A patent/MX2014004679A/es unknown
- 2012-10-19 PH PH1/2014/500856A patent/PH12014500856A1/en unknown
- 2012-10-19 CA CA2852417A patent/CA2852417A1/en not_active Abandoned
- 2012-10-19 KR KR1020147010504A patent/KR20140081826A/ko not_active Ceased
- 2012-10-19 UY UY0001034403A patent/UY34403A/es not_active Application Discontinuation
- 2012-10-19 EP EP12784752.3A patent/EP2768487B1/en active Active
- 2012-10-19 WO PCT/JP2012/077662 patent/WO2013058409A1/en not_active Ceased
- 2012-10-19 JP JP2014518853A patent/JP6093762B2/ja not_active Expired - Fee Related
- 2012-10-19 SG SG2014012025A patent/SG2014012025A/en unknown
-
2014
- 2014-04-11 TN TNP2014000152A patent/TN2014000152A1/en unknown
- 2014-04-13 IL IL232114A patent/IL232114A0/en unknown
- 2014-04-15 DO DO2014000077A patent/DOP2014000077A/es unknown
- 2014-04-17 CL CL2014000992A patent/CL2014000992A1/es unknown
- 2014-04-29 ZA ZA2014/03103A patent/ZA201403103B/en unknown
- 2014-04-29 EC ECSP14013328 patent/ECSP14013328A/es unknown
- 2014-05-09 CR CR20140213A patent/CR20140213A/es unknown
- 2014-05-14 CO CO14103846A patent/CO6960544A2/es unknown
- 2014-05-15 MA MA37034A patent/MA35717B1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530802A5 (OSRAM) | ||
| JP5937068B2 (ja) | 転用防止微粒剤および微小錠剤 | |
| JP5357032B2 (ja) | 誤用抵抗性製剤 | |
| AU2013356872B2 (en) | Oral form, comprising immediate-release coated particles of at least one active compound that are grinding-resistant | |
| ES2625092T3 (es) | Formas de dosificación orales resistentes a la adicción y método de uso de las mismas | |
| KR101940840B1 (ko) | 디아민 유도체 함유 의약 조성물 | |
| JP2009526021A5 (OSRAM) | ||
| WO2020071539A1 (ja) | 多孔性シリカ粒子組成物 | |
| MX2010008711A (es) | Composiciones farmaceuticas de entacapona, levopoda y carbidopa, con biodisponibilidad mejorada. | |
| TW201827049A (zh) | 含二胺衍生物之口腔崩散錠 | |
| JPH09500910A (ja) | パラセタモール及びドンペリドンのフィルムコーティング錠 | |
| US20130004550A1 (en) | Sustained-release solid preparation for oral use | |
| US10010510B2 (en) | Oral pharmaceutical formulation | |
| CN102178657B (zh) | 一种奥氮平口腔崩解片 | |
| EP2740471B1 (en) | Oral pharmaceutical composition comprising dabigatran etexilate | |
| JP2019500396A (ja) | 粘膜付着性医薬組成物及びその製造方法 | |
| UA82268C2 (uk) | Гранули, що містять гідрохлорид венлафаксину, та спосіб їх виготовлення | |
| EP3551171A1 (en) | Solid oral pharmaceutical compositions of ticagrelor | |
| JPWO2011121823A1 (ja) | 経口投与用粒子状医薬組成物 | |
| JP2008521932A5 (OSRAM) | ||
| HK1208130A1 (en) | Extended-release levetiracetam and method of preparation | |
| JP2012140335A (ja) | 不快味マスキング粒子及びこれを含有する経口製剤 | |
| JP5566757B2 (ja) | 固形製剤 | |
| JP2013023463A (ja) | 生理活性物質含有粒子の製造方法 | |
| JP2002012540A (ja) | 水易溶性薬物含有錠剤 |